Workflow
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates
CRLCharles River(CRL) ZACKS·2025-02-19 14:10

Core Viewpoint - Charles River Laboratories (CRL) reported quarterly earnings of 2.66pershare,exceedingtheZacksConsensusEstimateof2.66 per share, exceeding the Zacks Consensus Estimate of 2.50 per share, and showing an increase from 2.46pershareayearago[1][2].FinancialPerformance−Theearningssurpriseforthequarterwas6.402.46 per share a year ago [1][2]. Financial Performance - The earnings surprise for the quarter was 6.40%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2]. - Revenues for the quarter reached 1 billion, surpassing the Zacks Consensus Estimate by 2.79%, compared to 1.01billioninthesamequarterlastyear[3].−Thecompanyhasalsoexceededconsensusrevenueestimatesineachofthelastfourquarters[3].StockPerformanceandOutlook−CharlesRivershareshavedeclinedapproximately17.71.01 billion in the same quarter last year [3]. - The company has also exceeded consensus revenue estimates in each of the last four quarters [3]. Stock Performance and Outlook - Charles River shares have declined approximately 17.7% since the beginning of the year, while the S&P 500 has gained 4% [4]. - The current consensus EPS estimate for the upcoming quarter is 2.40, with expected revenues of 957.37million,andforthecurrentfiscalyear,theestimateis957.37 million, and for the current fiscal year, the estimate is 9.93 on $3.89 billion in revenues [8]. Industry Context - The Medical Services industry, to which Charles River belongs, is currently ranked in the bottom 47% of over 250 Zacks industries, indicating potential challenges ahead [9]. - The performance of the stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9].